Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 12/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 12/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114018 | 0.89 | CA1 (0.42) | ACSS2MAPK8MAPK9 | |
| SCHEMBL5115881 | 0.85 | CTSL (0.34) | CTSLCTNNB1TCF7L2CTSSCTSB | |
| SCHEMBL14131942 | 0.85 | CTSL (0.34) | CTSLCTNNB1TCF7L2CTSSCTSB | |
| SCHEMBL5107465 | 0.83 | CTNNB1 (0.47) | CTNNB1TCF7L2 | |
| SCHEMBL5114661 | 0.82 | VNN1 (0.39) | CTNNB1TCF7L2VNN1 | |
| SCHEMBL5117245 | 0.82 | VNN1 (0.39) | CTNNB1TCF7L2VNN1 | |
| SCHEMBL5123850 | 0.82 | MAPT (0.43) | MAPK8 | |
| SCHEMBL5115390 | 0.81 | CYP1A2 (0.42) | CTNNB1TCF7L2 | |
| SCHEMBL5121915 | 0.81 | MAP4K4 (0.46) | CTNNB1TCF7L2VNN1DGAT2 | |
| SCHEMBL5123118 | 0.80 | MAP4K4 (0.47) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | CTSL 848/4885CTNNB1 1384/4885TCF7L2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.